NEW YORK (GenomeWeb) – Rosetta Genomics today announced a nearly 800 percent jump in third quarter revenues from continuing operations as the company benefitted from the sale of products from PersonalizeDx, a molecular diagnostics firm acquired in April.

For the three-month period ended Sept. 30, Rosetta's revenues from continuing operations increased to $2.4 million from $273,000 in the same period last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.